Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV

Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballreich, Jeromie, Levengood, Timothy, Conti, Rena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Independent Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341204/
https://www.ncbi.nlm.nih.gov/pubmed/35902088
http://dx.doi.org/10.1017/jme.2022.33
_version_ 1784760563295846400
author Ballreich, Jeromie
Levengood, Timothy
Conti, Rena M.
author_facet Ballreich, Jeromie
Levengood, Timothy
Conti, Rena M.
author_sort Ballreich, Jeromie
collection PubMed
description Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations.
format Online
Article
Text
id pubmed-9341204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-93412042022-08-12 Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV Ballreich, Jeromie Levengood, Timothy Conti, Rena M. J Law Med Ethics Independent Articles Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization patterns and prices for generic PrEP. We discuss the opportunities and challenges for generic PrEP to improve health among HIV vulnerable populations. Cambridge University Press 2022 /pmc/articles/PMC9341204/ /pubmed/35902088 http://dx.doi.org/10.1017/jme.2022.33 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Independent Articles
Ballreich, Jeromie
Levengood, Timothy
Conti, Rena M.
Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title_full Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title_fullStr Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title_full_unstemmed Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title_short Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
title_sort opportunities and challenges of generic pre-exposure prophylaxis drugs for hiv
topic Independent Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341204/
https://www.ncbi.nlm.nih.gov/pubmed/35902088
http://dx.doi.org/10.1017/jme.2022.33
work_keys_str_mv AT ballreichjeromie opportunitiesandchallengesofgenericpreexposureprophylaxisdrugsforhiv
AT levengoodtimothy opportunitiesandchallengesofgenericpreexposureprophylaxisdrugsforhiv
AT contirenam opportunitiesandchallengesofgenericpreexposureprophylaxisdrugsforhiv

Ejemplares similares